

APPENDIX **XIII**

**TUMOR ASSOCIATED  
MUTATIONS IN JAK2**

Domain	Mutation	Tumor Type
FERM	p.F85S	RL-95-2 cells (endometrial carcinoma)
FERM	p.K191Q	Ovary serous carcinoma
Atypical SH2	p.C480F	MDA Pca 2b cells (prostate adenocarcinoma)
pfam B 15992	p.V536 I546dup11	PCV
pfam B 15992	p.F537 I546dup10+F547L	PCV
pfam B 15992	p.F537 K539>L	MF
		PCV
		Idiopathic erythrocytosis
pfam B 15992	p.H538 K539>QL	PCV
pfam B 15992	p.H538 K539>L	PCV
pfam B 15992	p.K539L	Idiopathic erythrocytosis
pfam B 15992	p.I540 E543>MK	PCV
pfam B 15992	p.R541 E543>K	PCV
		Idiopathic erythrocytosis
pfam B 15992	p.N542 E543del	PCV
		Idiopathic erythrocytosis
pfam B 15992	p.E543 D544del	PCV
		Idiopathic erythrocytosis
JH2	p.I546 F547ins11	PCV
JH2	p.K607N	AML (M0)
JH2	p.L611S	ALBL
JH2	p.C616Y	PCV
JH2	p.V617F	ALL

*Targeting Protein Kinases for Cancer Therapy*, by David J. Matthews and Mary E. Gerritsen  
Copyright © 2010 John Wiley & Sons, Inc.

## 2 TARGETING PROTEIN KINASES FOR CANCER THERAPY

		AML (M0, M1, M2, M4, M5, M6, M7)
		AMLAMDS
		AMLTR
		BPCML
		Budd–Chiari syndrome
		CELHS
		CML (Ph+ and Ph–)
		CMML
		CNL
		ET
		MCN
		MDS
		PCV MDSTR
		MF
		MPD
		BPET
		BPPCV
		Idiopathic erythrocytosis
		MPD
		Secondary erythrocytosis
		Systemic mastocytosis
JH2	p.V617F C618R	PCV
JH2	p.D620E	PCV
	p.E627E	PCV
	p.C675W	L1236 cells
PfamB 23637	p.I682 D686>	ALL
	p.I682 686Ddel	DS-BCP-ALL
	p.R683G	DS-ALL
	p.E846D	JEG-3 cells (placental choriocarcinoma)
Kinase	p.R1063H	JURL-MK1
		JURL-MK2 cells (myeloid leukemia)
Kinase	p.G1093R	22RV1 cells (prostate)
Kinase	p.R1117M	NCI-H358 cells (NSCLC cells)

## SOURCES

---

- Forbes SA, Bhamra G, Bamford S, Dawson E, Kok C, Clements J, Menzies A, Teague JW, Futreal PA, Stratton MR. The Catalog of Somatic Mutations in Cancer (COSMIC). *Curr Protocols Hum Genet*. 2008 Apr; Chapter 10: Unit 10.11.
- Mercher T, Wernig G, Moore SA, Levine RL, Gu TL, Frohling S, Cullen D, Polakiewicz RD, Bernard OA, Boggon TJ, Lee BH, Gilliland DG. JAK2T875N is a novel activating mutation that results in myeloproliferative disease with features of megakaryoblastic leukemia in a murine bone marrow transplantation model. *Blood* 2006;108(8):2770–2779.
- Pietra D, Li S, Brisci A, Passamonti F, Rumi E, Theoharides A, Ferrari M, Gisslinger H, Kralovics R, Cremonesi L, Skoda R, Cazzola M. Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. *Blood* 2008;111(3):1686–1689.
- Kearney L, Gonzalez De Castro D, Yeung J, Procter J, Horsley SW, Eguchi-Ishimae M, Bateman CM, Anderson K, Chaplin T, Young BD, Harrison CJ, Kempinski H, So CW, Ford AM, Greaves M. A specific JAK2 mutation (JAK2R683) and multiple gene deletions in Down syndrome acute lymphoblastic leukaemia. *Blood* 2009;113(3):646–648.
- Li S, Kralovics R, De Libero G, Theoharides A, Gisslinger H, Skoda RC. Clonal heterogeneity in polycythemia vera patients with JAK2 exon12 and JAK2-V617F mutations. *Blood* 2008;111(7):3863–3866.
- Lee JW, Kim YG, Soung YH, Han KJ, Kim SY, Rhim HS, Min WS, Nam SW, Park WS, Lee JY, Yoo NJ, Lee SH. The JAK2V617F mutation in de novo acute myelogenous leukemias. *Oncogene* 2006;25(9):1434–1436.
- Malinge S, Ben-Abdelali R, Settegrana C, Radford-Weiss I, Debre M, Beldjord K, Macintyre EA, Villevial JL, Vainchenker W, Berger R, Bernard OA, Delabesse E, Penard-Lacronique V. Novel activating JAK2 mutation in a patient with Down syndrome and B-cell precursor acute lymphoblastic leukemia. *Blood* 2007;109(5):2202–2204.
- Smith CA, Fan G. The saga of JAK2 mutations and translocations in hematologic disorders: pathogenesis, diagnostic and therapeutic prospects, and revised World Health Organization diagnostic criteria for myeloproliferative neoplasms. *Hum Pathol* 2008;39(6):795–810.

